Results 271 to 280 of about 28,823 (297)

Dipeptidyl peptidase 4 inhibitors

Reactions Weekly
openaire   +2 more sources

Sitagliptin: A Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

Annals of Pharmacotherapy, 2006
Shannon A Miller
exaly  

Dipeptidyl peptidase‐4 inhibitors and cardiovascular safety

Medical Journal of Australia, 2014
openaire   +2 more sources

Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes

Expert Opinion on Pharmacotherapy, 2016
Jingbo Hu
exaly  

Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Protects Endothelial Function in Hypertension Through a Glucagon–Like Peptide 1–Dependent Mechanism

Hypertension, 2012
Limei Liu, Wing Tak Wong, Xiao Yu Tian
exaly  

Dipeptidyl peptidase-4 inhibitor reduces infarct size and preserves cardiac function via mitochondrial protection in ischaemia–reperfusion rat heart

Diabetes and Vascular Disease Research, 2014
Kroekkiat Chinda, , Nipon Chattipakorn
exaly  

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

Clinical Therapeutics, 2008
Aziz Karim
exaly  

Dipeptidyl‐Peptidase‐4 Inhibitor, Alogliptin, Attenuates Arterial Inflammation and Neointimal Formation After Injury in Low‐Density Lipoprotein (LDL) Receptor‐Deficient Mice

Journal of the American Heart Association, 2015
Koji Akita, Kikuo Isoda, Kazunori Shimada   +2 more
exaly  

The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

Expert Opinion on Pharmacotherapy, 2013
Masanori Abe, Terumi Higuchi, Noriaki Maruyama   +2 more
exaly  

Synthesis of a Dipeptidyl Peptidase 4 Inhibitor

Synfacts, 2009
openaire   +1 more source